Compare UCTT & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCTT | URGN |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2004 | 2017 |
| Metric | UCTT | URGN |
|---|---|---|
| Price | $25.33 | $28.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $32.50 | $28.50 |
| AVG Volume (30 Days) | 467.0K | ★ 1.3M |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,110,600,000.00 | $96,516,000.00 |
| Revenue This Year | N/A | $35.07 |
| Revenue Next Year | $5.74 | $117.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.65 | ★ 8.00 |
| 52 Week Low | $16.66 | $3.42 |
| 52 Week High | $40.64 | $30.00 |
| Indicator | UCTT | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 72.41 |
| Support Level | $21.49 | $24.69 |
| Resistance Level | $25.73 | $30.00 |
| Average True Range (ATR) | 1.25 | 1.56 |
| MACD | 0.26 | 0.36 |
| Stochastic Oscillator | 73.20 | 79.38 |
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments Products and Services. Its principal markets are Americas, Asia Pacific and EMEA.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.